Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan

@article{Sato2012ImpactOT,
  title={Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan},
  author={Daisaku Sato and Yasunori Sato and Sachiko Masuda and Hiromichi Kimura},
  journal={International Journal of Clinical Pharmacy},
  year={2012},
  volume={34},
  pages={917-924}
}
Background Sitagliptin, the first of a new class of dipeptidyl peptidase-4 (DPP-4)-inhibitory oral antihyperglycemic drugs (OHDs), was introduced in Japan in December 2009. In April 2010 a safety alert was issued regarding the risk of serious hypoglycemic events when the drug is used in combination with high-dose sulfonylureas (SUs). Objective To investigate trends in prescription of OHDs before and after the launch of sitagliptin, and before and after the safety alert, in order to evaluate… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 12 REFERENCES

the Risks from Medical Product Use, 1999 (on line)

US FDA. Managin
  • Available from URL: http://www.fda.gov/downloads/ safety/safetyofspecificproducts/ucm180520.pdf. Accessed 19 Jun
  • 2012
VIEW 1 EXCERPT

A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin

AS Gangji, CH Goldsmith, T Cukierman, CM Clase, HC. Gerstein
  • Diabetes Care
  • 2007
VIEW 1 EXCERPT

Old but new oral hyperglycemic drug-effectiveness of metformin

Y. Iwamoto
  • Med Drug J
  • 2007
VIEW 1 EXCERPT

Pharmacoepidemiological study on incidence of hypoglycemia by diabetes medication

M Hayashi, S Suzuki, Y Yambe, Y Katou, M. Niinomi
  • J Jpn Diabetes Soc
  • 2006
VIEW 1 EXCERPT